The latest inspection comes 2 1/2 years after the agency allowed Sun Pharma to keep shipping some drugs to Americans even ...

India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the ...

Sun Pharmaceutical Industries Ltd. closed 14.19% short of its 52-week high of 1,960.20 rupees, which the company reached on ...

Discover the Sun Pharma Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

In a regulatory filing on Monday, Sun Pharma announced that it has reached a settlement and licensing agreement with Incyte ...

Sun Pharmaceutical Industries Ltd. closed 13.62% below its 52-week high of 1,960.20 rupees, which the company reached on September 30th.

LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...

Sun Pharmaceutical Industries, announced its release of Leqselvi in the U.S. earlier this week. Leqselvi™ is currently ...

Sun Pharma settles litigation with Incyte, gains license for alopecia treatment, launches LEQSELVI tablet in the US.

After resolving a patent dispute with Incyte, Sun Pharma has officially launched its JAK inhibitor Leqselvi in the U.S. | Sun ...

Sun Pharma settles litigation with Incyte over Leqselvi, launches product for severe alopecia areata treatment in the US.